Mark Enyedy, ImmunoGen CEO
ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval
When ImmunoGen’s lead antibody-drug conjugate flunked a Phase III study in ovarian cancer a couple years ago, the company clung to hope that it would perform better in a subgroup of patients with high folate receptor alpha (FRα) expression.
On Tuesday, researchers uncorked topline Phase III results suggesting it was right — and investors cheered on the news with a 40% boost to ImmunoGen’s stock price $IMGN. CEO Mark Enyedy says he’s going after an accelerated approval and plans to file in the first quarter of 2022.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters